Ipamorelin Legal & Patent Challenges: FDA Status, Compounding Rules, and Safety

Is ipamorelin FDA-approved?

No. Ipamorelin is not a component of any FDA-approved drug, and it has no US Pharmacopeia monograph [1][9]. It is a five-amino-acid synthetic peptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, that releases growth hormone by acting at the ghrelin/GH-secretagogue receptor rather than the GHRH receptor, and it contains unnatural amino acids [1][9]. It was identified in 1998 and developed as an investigational drug for postoperative ileus; that development was reportedly discontinued after disappointing phase 2 results [1][9].

Can compounding pharmacies legally make ipamorelin?

Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before they reach patients [10]. FDA runs one framework for bulk substances used by state-licensed pharmacies filling patient-specific prescriptions, and another for registered outsourcing facilities, which may also supply in response to an order from a health care provider that is not for an identified patient [10].

Large outsourcing facilities

FDA lists ipamorelin acetate among bulk substances that may present significant safety risks (category 2) for outsourcing facilities. It was added September 29, 2023, and it is still on that list on FDA's page dated April 22, 2026 and on the version updated March 21, 2025 — one of the few peptides still in category 2 [2][4].

FDA's stated concerns are three: possible immunogenicity for certain routes of administration because of aggregation and peptide-related impurities; unnatural amino acids that complicate characterization; and a published study that, in FDA's words, 'identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility.' FDA adds that it 'has not identified safety-related information' for other injectable routes [2].

State-licensed pharmacies

Ipamorelin appears in FDA's 'nominated but withdrawn' table — those nominations were withdrawn by the nominator — and in none of the three categories on FDA's bulk-substance list updated May 14, 2026 [2][5]. FDA's category 1 policy, under which the agency generally takes no action against compounders that meet the conditions, does not apply to it [2][5].

What did FDA's advisory committee decide?

FDA reviewers proposed that ipamorelin not be added to the pharmacy bulks list. On October 29, 2024 the Pharmacy Compounding Advisory Committee voted 0 yes, 12 no, 1 abstention on ipamorelin free base, and the same — 0 yes, 12 no, 1 abstention — on ipamorelin acetate. The committee cited a lack of information supporting safety and efficacy for growth hormone deficiency and postoperative ileus [3].

Does the October 2026 HHS peptide policy cover ipamorelin?

No. HHS's October 2026 draft enforcement-discretion policy names six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Ipamorelin is not one of them, and no FDA or HHS action allowing compounding of ipamorelin has been identified [6].

Is ipamorelin banned in sport?

Yes. WADA's 2026 Prohibited List names ipamorelin in S2.2.4, growth hormone secretagogues and their mimetics. It is prohibited at all times, in and out of competition, and S2 substances are non-Specified Substances; the 2027 List, in force January 1, 2027, names it as well [7][11]. FDA notes that ipamorelin has been found in vials confiscated from athletes [1].

What safety concerns does FDA list?

Two.

The first is the published ileus trial data. In that phase 2 study, low potassium occurred in 12.5% of ipamorelin patients versus 3.4% on placebo; insomnia in 10.7% versus 5.2%; high blood sugar at discharge in 14.3% versus 8.6%; serious adverse events in 17.9% versus 15.5%. Two ipamorelin-treated patients died of surgical complications — bowel surgery for colon cancer with an anastomotic leak. FDA said it is unclear whether the deaths were related to ipamorelin, but that they raise safety concerns [1][8].

The second is the growth hormone axis. Ipamorelin stimulates GH and IGF-1, so FDA says it may carry the risks listed on approved growth hormone labels — neoplasm, glucose intolerance and diabetes, intracranial hypertension, fluid retention, hypothyroidism, pancreatitis and others — and, like the approved GH stimulator macimorelin, possibly QT prolongation. FDA found no data showing it would not [1].

What did the human trials actually show?

The one published phase 2 trial (Beck et al., 2014) was multicenter, randomized, double-blind and placebo-controlled: 117 adults were enrolled and 114 analyzed after bowel resection, with 0.03 mg/kg intravenous ipamorelin or placebo twice daily from postoperative day 1 to 7. Median time to first tolerated solid meal was 25.3 hours with ipamorelin and 32.6 hours with placebo (p=0.15, not significant). Secondary GI-recovery endpoints did not differ; only a subgroup of open-surgery patients showed shorter bowel recovery. Any treatment-emergent adverse event occurred in 87.5% versus 94.8% [8].

FDA's October 2024 review identified only one published ipamorelin study for postoperative ileus [1].

The pharmacokinetic work in healthy volunteers used 15-minute intravenous infusions of 4.21 to 140.45 nmol/kg: dose-proportional kinetics, a terminal half-life of about 2 hours, and a single GH peak about 0.67 hours after the infusion [12]. There is no approved dose. FDA found no human pharmacokinetic, safety or efficacy data for subcutaneous ipamorelin [1], so the intravenous doses above are study doses, not recommendations.